Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2020 - 12 - 21 tags : Phase 3 save search
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study
Published: 2020-12-21 (Crawled : 22:00) - globenewswire.com
MTEM | $1.5 2.04% 3.29% 27K
|
Health Technology
|
| O: 2.48%
H: 10.49%
C: 9.18%
molecular phase 3 phase 1 phase 2
Principle LTC's Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention
Published: 2020-12-21 (Crawled : 17:00) - biospace.com/
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: -1.47%
H: 0.07%
C: -0.06%
covid drug phase 3 trial
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
Published: 2020-12-21 (Crawled : 16:00) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 16.12%
H: 0.18%
C: -7.82%
cancer phase 3 therapy ovarian cancer
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
BMRN | $89.49 0.97% 0.99% 1.3M
|
Health Technology
|
| O: -3.07%
H: 1.83%
C: 1.61%
drop phase 3 children achondroplasia
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
EXEL | $22.87 1.55% 1.49% 1.5M
|
Health Technology
|
| O: 0.55%
H: 0.2%
C: 0.05%
cancer phase 3 trial
Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
TSHA | $2.46 8.37% 7.35% 1.5M
|
Health Technology
|
| O: -0.94%
H: 2.89%
C: -0.05%
approval therapy gene therapies trial phase 3 phase 1 phase 2 gene therapy tsha-102
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Published: 2020-12-21 (Crawled : 13:03) - globenewswire.com
MBIO | $0.34 -0.47% 9.7% 300K
|
Health Technology
|
| O: 0.97%
H: 5.47%
C: 4.5%
trial phase 3 phase 1 phase 2 t-cell car-t train
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
TNXP | $0.1554 -2.88% -1.33% 1.4M
|
Health Technology
|
| O: -6.0%
H: 5.73%
C: 2.17%
results phase 3 topline
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
Published: 2020-12-21 (Crawled : 12:01) - globenewswire.com
BCRX | News | $4.41 -0.45% -0.45% 1.8M
|
Health Technology
|
| O: 0.58%
H: 0.75%
C: -4.16%
results positive treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.